Clinical trials: Hereditary Nephritis
Cystinuria, Renal Lithiasis
Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria
It has recently been described the presence of a urinary inflammatory signature in patients with cystinuria, the most common cause of renal lithiasis of genetical origin.
- Conditions
- Cystinuria, Renal Lithiasis, Glomerulonephritis, Interstitial Nephritis
- Trial name
- NCT03836144
- Testing
- Potassium citrate
- Where
- France
- Volunteers
- 63 people
- Sponsor
- European Georges Pompidou Hospital
Alport Syndrome
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome
Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function. To assess the safety and tolerability of lademirsen (SAR339375) in participants with Alport syndrome.
- Trial name
- HERA (NCT02855268)
- Testing
- lademirsen (SAR339375)
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 43 people
- Sponsor
- Genzyme, a Sanofi Company
Renal Insufficiency, Chronic
Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome
This is a phase III, multi-centre, randomised, placebo-controlled, patient and investigator-blind study in paediatric patients with early stages of Alport syndrome to assess the safety and efficacy of the ACEi ramipril in slowing…
- Trial name
- NCT01485978
- Testing
- Ramipril
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Nephritis, Hereditary, Hematuria-Nephropathy-Deafness Syndrome
Biomarker for Alport Syndrome (BioAlport)
International, multicenter, observational, longitudinal monitoring study to identify biomarker/s for Alport syndrome and to explore the clinical robustness, specificity, and long-term variability of these biomarker/s
- Trial name
- BioAlport (NCT02718027)
- Where
- 7 sites in Albania, Georgia and 5 more
- Volunteers
- 12 people
- Sponsor
- CENTOGENE GmbH Rostock
Alport Syndrome
Human Umbilical Cord Mesenchymal Stem Cells for Alport Syndrome
The goal of this clinical trial is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in the treatment of Alport syndrome (AS) in a randomized, single-blind, placebo-controlled trial, to…
- Trial name
- HUCMSC (NCT06731192)
- Testing
- hUC-MSC
- Volunteers
- 40 people
- Sponsor
- Guangzhou Women and Children's Medical Center
Nephritis, Interstitial, Chronic Renal Failure
Hereditary Tubulointerstitial Nephritis
The aim of this study is to identify families with hereditary chronic tubulointerstitial renal diseases , characterize the phenotype and screen for mutations in known genesis (UMOD, REN, TCF2, NPHP1).
- Conditions
- Nephritis, Interstitial, Chronic Renal Failure, Gout, Renal Cysts
- Trial name
- NTIH (NCT01312727)
- Testing
- Blood and urine sample collections
- Where
- France
- Volunteers
- 225 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Kidney Diseases, Alport Syndrome
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
This extended access study will assess the long-term safety and tolerability of bardoxolone methyl in qualified patients with chronic kidney disease (CKD) who previously participated in one of the qualifying clinical studies with…
- Conditions
- Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
- Trial name
- EAGLE (NCT03749447)
- Testing
- Bardoxolone methyl
- Where
- 87 sites in United States, Australia and 4 more
- Volunteers
- 270 people
- Sponsor
- Biogen
IgA Nephropathy, CKD Associated With Type 1 Diabetes
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes…
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Trial name
- PHOENIX (NCT03366337)
- Testing
- Bardoxolone methyl capsules
- Where
- 30 sites in United States
- Volunteers
- 103 people
- Sponsor
- Biogen
Alport Syndrome
Alport Syndrome Treatments and Outcomes Registry
ASTOR's primary purpose is to enroll families and patients with a history of Alport syndrome in a central registry. The information we gather will be used as a basis for studies designed to test potential treatments for Alport…
- Trial name
- ASTOR (NCT00481130)
- Where
- United States
- Volunteers
- 655 people
- Sponsor
- University of Minnesota
Alport Syndrome, X-Linked
Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)
This Phase 2 randomized controlled trial will study the safety, tolerability, and efficacy of Hydroxychloroquine in qualified patients with Alport syndrome.
- Trial name
- CHXLAS (NCT04937907)
- Testing
- Hydroxychloroquine Sulfate 100 milligram (mg) Tab, Benazepril hydrochloride 10 milligram (mg) Tab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Children's Hospital
SIOD, Cystinosis
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
This is a single center, non-randomized, non-controlled open-label phase 1b/2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney rejection post-KT, in the absence of any post-KT…
- Conditions
- SIOD, Cystinosis, FSGS, SLE Nephritis
- Trial name
- NCT05508009
- Testing
- Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Alice Bertaina
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Collagen Type-4 Nephropathies
Enalapril in Collagen Type 4 Nephropathy
Background: Collagen IV-related nephropathies can lead to End Stage Renal Disease. Experimental studies have shown renin angiotensin aldosterone system blockade can reduce proteinuria and preserve renal function.
- Trial name
- NCT01465126
- Volunteers
- 19 people
- Sponsor
- University of Sao Paulo
Fibrosis, Focal Glomerulosclerosis
Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
This study will examine the effectiveness of the drug pirfenidone in treating focal segmental glomerulosclerosis (FSGS). Patients with this disease have kidney fibrosis (scarring) and proteinuria (excessive excretion of protein…
- Conditions
- Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome
- Trial name
- NCT00001959
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Alport Syndrome, Metformin
Treatment With Metformin in Chinese Children With Alport Syndrome
This single-center, prospective, double-blind randomized placebo-controlled trial will evaluate the efficacy and safety of metformin in Chinese children with Alport syndrome who have received (and continue to receive)) ACEi/ARB.
- Trial name
- NCT05655728
- Testing
- Metformin
- Volunteers
- 78 people
- Sponsor
- Peking University First Hospital
Chronic Kidney Failure in Children and Young Adults
Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients
Recent trials have demonstrated positive renal outcomes of sodium-glucose co-transporter-2 inhibitors (SGLT2i) additive to angiotensin-converting-enzyme inhibitors (ACEis) in adult patients with diabetic and non-diabetic chronic…
- Trial name
- DOUBLE_PROTECT (NCT05944016)
- Testing
- Dapagliflozin
- Where
- 16 sites in Germany
- Volunteers
- 102 people
- Sponsor
- University Hospital Goettingen
Alport Nephropathy
Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy.
This biomarker study is a follow-up to CPLATFRM2201. The goal of CBASICHR0005 is to collect another urine sample, interval clinical information, and an optional DNA sample from as many of the original 80 patients as possible.
- Trial name
- NCT03074357
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Lupus Nephritis (LN)
The Role of Transforming Growth Factor- Beta (TGF- β) Expression in Renal Biopsy of Lupus Nephritis Patients
To investigate the possible role of TGF-β expression in renal biopsy and it's relation with fibrosis, activity and chronicity indices
- Trial name
- NCT07823556
- Testing
- renal biopsy
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Alport Syndrome
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL
This international, multi-center, Phase 2/3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with Alport syndrome.
- Trial name
- CARDINAL (NCT03019185)
- Testing
- Bardoxolone Methyl
- Where
- 63 sites in United States, Australia and 6 more
- Volunteers
- 187 people
- Sponsor
- Biogen
Alport Syndrome
Urinary Biomarkers of the Progression of Alport Kidney Disease
The purpose of the study is to determine if there are certain laboratory tests that can be performed to detect substances or features in a child's urine that can be used to measure the progress of Alport kidney disease and the…
- Trial name
- NCT01705132
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Minnesota